Cortisol in the Treatment of Phobias

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00451750
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : January 12, 2010
University Hospital, Basel, Switzerland
Information provided by:
University of Zurich

Brief Summary:
The aim of this prospective, double-blind, placebo-controlled, randomized study is to investigate if glucocorticoid treatment, in combination with exposure therapy, helps to reduce phobic fear in patients with phobia.

Condition or disease Intervention/treatment Phase
Phobia Drug: Cortisol Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias
Study Start Date : May 2007
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Intervention Details:
  • Drug: Cortisol
    20 mg for 3 times

Primary Outcome Measures :
  1. visual analog scales for fear and acrophobia questionnaires [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Female and male patients with a specific phobia (fear of heights) according to DSM-IV criteria.

Exclusion Criteria:

  • Severe acute or chronic somatic diseases
  • Psychiatric disorder other than specific phobia
  • Topic glucocorticoid therapy (for large skin parts)
  • Inhaled glucocorticoids
  • Psychotropic medication
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00451750

University of Basel
Basel, Switzerland, 4055
Sponsors and Collaborators
University of Zurich
University Hospital, Basel, Switzerland
Principal Investigator: Dominique JF de Quervain, MD, Prof. University of Zurich
Principal Investigator: Frank Wilhelm, Prof. University of Basel

Responsible Party: Dominique de Quervain, Prof. MD, University of Zurich Identifier: NCT00451750     History of Changes
Other Study ID Numbers: 2007DR3069
First Posted: March 23, 2007    Key Record Dates
Last Update Posted: January 12, 2010
Last Verified: January 2010

Keywords provided by University of Zurich:

Additional relevant MeSH terms:
Phobic Disorders
Anxiety Disorders
Mental Disorders
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Cortisol succinate
Anti-Inflammatory Agents